InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
8
Disclosed sells
0
T+90 hit rate
14%
T+90 mean return
-19.6%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Sims Andrew John Hugh MacIntyre, Chief Financial Officer. Officer active across 1 company, notably Plus Therapeutics, INC.. Cumulatively, 12 filings have been logged. Breakdown: 8 buys · 0 sell. Total volume traded: €35k. History available since 27 July 2021. The latest transaction was filed on 1 April 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Sims Andrew John Hugh MacIntyre
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
38,323 shares0Common StockSEC:0001193125-26-135711:0
29,129 shares0Common StockSEC:0001193125-26-135711:1
38,323 shares0Common StockSEC:0001193125-26-000966:0
20,000 shares@ US$0.5125.5% of flowCommon StockSEC:0001193125-25-265866:0
Canonical exit: 2 Feb 2026 (T+90)
38,323 shares0Common StockSEC:0001193125-25-230291:0
4,098 shares@ US$1.2714.0% of flowCommon StockSEC:0000950170-24-105330:0
Canonical exit: 9 Dec 2024 (T+90)
4,902 shares@ US$2.0427.6% of flowCommon StockSEC:0000950170-24-057456:0
Canonical exit: 6 Aug 2024 (T+90)
3,000 shares@ US$0.6725.5% of flowCommon StockSEC:0001209191-22-025719:0
Canonical exit: 25 Jul 2022 (T+90)
2,000 shares@ US$1.09995.7% of flowCommon StockSEC:0001209191-22-015201:0
Canonical exit: 30 May 2022 (T+90)
1,000 shares@ US$1.86434.6% of flowCommon StockSEC:0001209191-21-062868:0
Canonical exit: 31 Jan 2022 (T+90)
2,000 shares@ US$1.66948.3% of flowCommon StockSEC:0001209191-21-061723:0
Canonical exit: 24 Jan 2022 (T+90)
1,986 shares@ US$2.059.9% of flowCommon StockSEC:0001209191-21-048660:0
Canonical exit: 25 Oct 2021 (T+90)
12 of 12 declarations
About Sims Andrew John Hugh MacIntyre
Sims Andrew John Hugh MacIntyre is Directeur Financier and Chief Financial Officer at Plus Therapeutics, INC. He has 12 filings in total, and in the recent filings sampled, purchases total EUR 34667 with no sales reported, between 2021-07-29 and 2026-04-01. The most common transaction nature is Acquisition.
